Presents One-Year Outcomes from the LANDMARK Randomized Controlled TrialVAPI, India, Nov. 25, 2025 /PRNewswire/ -- Underscoring India's rising influence in…
Company Announces Approximately $30 Million in Cash and Short-Term Investments Following Its October 27th Registered Direct Offering November 24, 2025…
Company confirms 12 patients enrolled in Phase 2 THIO-101 to date as expansion trial adds new countries Posters for Phase…
November 08, 2025 17:13 ET | Source: Intellia Therapeutics, Inc. Deep, stable and durable reductions in kallikrein observed Among 32 patients…
THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical…
DALLAS, Nov. 4, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc. announced today positive long-term safety results from its EXTEND study, a…
Results presented at the 17th World Stroke Congress (WSC 2025) LT3001(Odatroltide)-202 phase 2b study met primary endpoint. No symptomatic intracranial…
October 31, 2025 16:30 ET | Source: FibroBiologics, Inc. Advancing preparations to begin manufacturing of fibroblast-based spheroids product candidate, CYWC628,…
SHANGHAI, Oct. 30, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II…
MINNEAPOLIS, United States and BRISBANE, Australia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company)…